tocilizumab - versus placebo - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.97 [0.72, 1.32]< 10%2 studies (2/-)56.7 %some concernnot evaluable moderatecrucial-
deaths 1.03 [0.77, 1.38]< 10%2 studies (2/-)42.1 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 1.03 [0.77, 1.38]< 10%2 studies (2/-)42.1 %some concernnot evaluable moderatecrucial-
clinical improvement 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %NAnot evaluable important-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %NAnot evaluable important-
death or ventilation 0.98 [0.72, 1.34]< 10%1 study (1/-)55.1 %NAnot evaluable important-
hospital discharge 0.97 [0.79, 1.20]> 10%1 study (1/-)38.9 %NAnot evaluable important-
mechanical ventilation 0.67 [0.39, 1.14]< 10%1 study (1/-)93.0 %NAnot evaluable important-
ICU admission 0.48 [0.25, 0.94]< 10%1 study (1/-)98.4 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.82 [0.63, 1.07]< 10%2 studies (2/-)92.4 %some concernnot evaluable moderateimportant-
adverse events 1.11 [0.74, 1.67]< 141%2 studies (2/-)29.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.